Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -189.51% is 70% above its 5-year average of -625.76%, near the high end of its 5-year range (-1945.86%–94.42%).
65.80% above its 12-month average of -554.11%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -587.08%.
EBITDA MARGIN
-189.51%
EBITDA MARGIN AVG TTM
-554.11%
EBITDA MARGIN AVG 3Y
-878.50%
EBITDA MARGIN AVG 5Y
-625.76%
EBITDA MARGIN AVG 10Y
-1072.79%
EBITDA MARGIN AVG 15Y
-708.67%
EBITDA MARGIN AVG 20Y
-484.02%
CURRENT VS TTM AVG
+65.80%
CURRENT VS 3Y AVG
+78.43%
CURRENT VS 5Y AVG
+69.72%
CURRENT VS 10Y AVG
+82.33%
CURRENT VS 15Y AVG
+73.26%
CURRENT VS 20Y AVG
+60.85%
Arbutus Biopharma Corp
Market Cap
$891.39M
EBITDA Margin
-189.51%
TTM Avg
-554.11%
3Y Avg
-878.50%
5Y Avg
-625.76%
Market Cap
$879.59M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$872.19M
EBITDA Margin
43.46%
TTM Avg
29.10%
3Y Avg
-0.91%
5Y Avg
-6.21%
Market Cap
$916.63M
EBITDA Margin
20.95%
TTM Avg
21.20%
3Y Avg
20.44%
5Y Avg
19.67%
Market Cap
$865.70M
EBITDA Margin
-9.76%
TTM Avg
-14.11%
3Y Avg
-27.72%
5Y Avg
-36.15%
Market Cap
$857.96M
EBITDA Margin
-170.39%
TTM Avg
-102.27%
3Y Avg
-63.10%
5Y Avg
-63.10%
Market Cap
$849.02M
EBITDA Margin
-37.08%
TTM Avg
-66.80%
3Y Avg
-66.80%
5Y Avg
-66.80%
Market Cap
$845.57M
EBITDA Margin
-17.48%
TTM Avg
-35.83%
3Y Avg
-4.31%
5Y Avg
17.66%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $891.39M | -189.51% | -554.11% | -878.50% | -625.76% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $879.59M | N/A | N/A | N/A | N/A |
| Bioventus Inc. (BVS)vs › | $901.73M | 18.58% | 12.56% | -0.37% | 4.16% |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $872.19M | 43.46% | 29.10% | -0.91% | -6.21% |
| HealthStream, Inc. (HSTM)vs › | $916.63M | 20.95% | 21.20% | 20.44% | 19.67% |
| SI-BONE, Inc. (SIBN)vs › | $865.70M | -9.76% | -14.11% | -27.72% | -36.15% |
| SL Science Holding Ltd (SLBT)vs › | $857.96M | -170.39% | -102.27% | -63.10% | -63.10% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $849.02M | -37.08% | -66.80% | -66.80% | -66.80% |
| QuidelOrtho Corporation (QDEL)vs › | $845.57M | -17.48% | -35.83% | -4.31% | 17.66% |
| CeriBell, Inc. (CBLL)vs › | $933.39M | -64.07% | -61.50% | -81.15% | -81.15% |
Gross Margin
100.0%
EBITDA Margin
-189.5%
Operating Margin
-192.1%
Net Margin
84.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -587.08% |
| 2026-03-31 | 94.42% |
| 2025-12-31 | -726.26% |
| 2025-09-30 | -1565.60% |
| 2025-06-30 | 13.96% |
| 2025-03-31 | -1945.86% |
| 2024-12-31 | -864.04% |
| 2024-09-30 | -1576.10% |
| 2024-06-30 | -1229.84% |
| 2024-03-31 | -1240.73% |
| 2023-12-31 | -950.49% |
| 2023-09-30 | -454.89% |
| 2023-06-30 | -387.94% |
| 2023-03-31 | -255.41% |
| 2022-12-31 | -356.37% |
| 2022-09-30 | -293.48% |
| 2022-06-30 | -96.38% |
| 2022-03-31 | -84.10% |
| 2021-12-31 | -635.34% |
| 2021-09-30 | -537.75% |
| 2021-06-30 | -781.71% |
| 2021-03-31 | -720.92% |
| 2020-12-31 | -662.78% |
| 2020-09-30 | -966.97% |
| 2020-06-30 | -834.87% |
| 2020-03-31 | -848.22% |
| 2019-12-31 | -774.29% |
| 2019-09-30 | -2969.42% |
| 2019-06-30 | -3064.32% |
| 2019-03-31 | -2733.73% |
| 2018-12-31 | -977.29% |
| 2018-09-30 | -2011.91% |
| 2018-06-30 | -1725.72% |
| 2018-03-31 | -1239.76% |
| 2017-12-31 | -2353.16% |
| 2017-09-30 | -178.53% |
| 2017-06-30 | -1829.16% |
| 2017-03-31 | -7644.68% |
| 2016-12-31 | 131849.74% |
| 2016-09-30 | -2413.95% |
| 2016-06-30 | -63105.50% |
| 2016-03-31 | -3276.95% |
| 2015-12-31 | -91.35% |
| 2015-09-30 | -1426.45% |
| 2015-06-30 | -420.59% |
| 2015-03-31 | -382.02% |
| 2014-12-31 | -244.46% |
| 2014-09-30 | -153.85% |
| 2014-06-30 | -512.09% |
| 2014-03-31 | -131.47% |
| 2013-12-31 | -30.57% |
| 2013-09-30 | -118.26% |
| 2013-06-30 | -102.63% |
| 2013-03-31 | -132.68% |
| 2012-12-31 | -150.92% |
| 2012-09-30 | -51.13% |
| 2012-06-30 | -65.10% |
| 2012-03-31 | -67.17% |
| 2011-12-31 | -51.66% |
| 2011-09-30 | -35.15% |
| 2011-06-30 | -76.77% |
| 2011-03-31 | -65.33% |
| 2010-09-30 | 35.63% |
| 2010-06-30 | -155.90% |
| 2010-03-31 | -161.64% |
| 2009-12-31 | -44.31% |
| 2009-09-30 | -61.27% |
| 2009-06-30 | -44.55% |
| 2009-03-31 | -59.36% |
| 2008-12-31 | -153.79% |
| 2008-09-30 | -55.75% |
| 2008-06-30 | -196.22% |
| 2008-03-31 | -38.22% |
| 2007-12-31 | 6.62% |
| 2007-09-30 | 30.01% |
| 2007-06-30 | 10.21% |
